Ivermectin Sensitivity in Dogs (mdr1 Gene Defect)
- Occurrence: rarer
- Location of disease: General/Whole body
When to visit the vet?
Non-urgent see a veterinarian within 2–3 days
If the condition worsens / symptoms persist, consult a veterinarian.
Definition
The mdr1 gene defect, also known as ivermectin sensitivity, is a genetic mutation in dogs that leads to increased sensitivity to certain medications, especially those affecting the central nervous system.
Das Wichtigste auf einen Blick
The mdr1 gene defect affects the MDR1 gene, which encodes P-glycoprotein, an important protein for protecting the brain. In dogs with this genetic defect, the function of the protein is impaired, allowing certain medications to enter the brain in toxic amounts. This can lead to severe neurological symptoms. The mutation is autosomal recessive; affected dogs must have two copies of the defective gene. The defect occurs particularly frequently in breeds such as Collies and Australian Shepherds. Symptoms can range from Disorientation and tremors to seizures. Diagnosis is made through genetic testing that confirms the presence of the mutation. Treatment consists primarily of avoiding problematic medications. Should a dog nevertheless be exposed to such a medication, immediate veterinary treatment is required. The prognosis for affected dogs is good if problematic medications are avoided. Prevention begins with genetic testing of breeding animals to reduce the spread of the mutation. Research focuses on the prevalence of the defect, the development of safe treatment strategies, and understanding the genetic basis of the defect.
Ursachen
The mdr1 gene defect affects the MDR1 gene (Multidrug Resistance Gene 1), which is responsible for the production of a protein called P-glycoprotein. This protein plays a crucial role in protecting the brain by regulating the transport of certain substances across the blood-brain barrier. In dogs with this mutation, the function of this protein is impaired.
The absence or malfunction of P-glycoprotein allows certain medications, which are normally kept out of the brain, to enter in toxic concentrations. This can lead to severe neurological symptoms. The mutation is autosomal recessive, meaning that dogs must carry two copies of the defective gene to be affected.
The cause of the mdr1 gene defect is genetic. Certain dog breeds are predisposed, including Collies, Australian Shepherds, Shetland Sheepdogs, and others. The mutation is likely due to a common ancestor, and its prevalence in certain breeds indicates selective breeding practices that unintentionally passed on the defective gene.
Symptoms
Dogs with the mdr1 gene defect show symptoms when exposed to certain medications. Common symptoms include neurological signs such as tremors, Convulsions, ataxia (Coordination disorders), lethargy, and in severe cases, coma. These symptoms are due to the toxic effect of the medications on the central nervous system.
The severity of symptoms can vary depending on the medication dose, the dog’s size, and the extent of the gene mutation. In some cases, gastrointestinal symptoms such as Vomiting and Diarrhea may also occur, indicating a systemic reaction of the body.
Diagnose
The diagnosis of an mdr1 gene defect is usually made through genetic testing. A simple cheek swab or blood sample can be used to analyze the MDR1 gene. The test checks whether the dog is a carrier of the defective gene or actually has two copies of the mutated gene, making it susceptible to the symptoms.
In addition to genetic testing, the veterinarian can make a clinical diagnosis based on the dog’s history, symptoms, and response to certain medications. If a dog shows symptoms after administration of a known problematic medication, this can be a strong indication of an mdr1 gene defect.
Therapie
The treatment for dogs with the mdr1 gene defect primarily involves avoiding the administration of the affected medications. If a dog is accidentally exposed to one of these medications, immediate veterinary treatment may be necessary to alleviate symptoms and prevent complications. This may include administering activated charcoal to reduce the absorption of the medication or giving drugs to control Convulsions.
Long-term, it is important for pet owners and veterinarians to be aware of which medications should be avoided in affected dogs. These include ivermectin, some antiparasitics, certain antibiotics, and pain relievers. Close collaboration with the veterinarian is crucial to find alternative medications that are safe for the dog.
Prognose und Nachsorge
The prognosis for dogs with an mdr1 gene defect is generally good, provided that the problematic medications are avoided. Dogs can lead a normal, healthy life if they are properly monitored and treated. In cases where a dog is accidentally exposed to a problematic medication, the prognosis depends on prompt treatment and the severity of the symptoms.
It is important to note that the mdr1 gene defect is a lifelong condition that requires continuous monitoring. However, with the right precautions and care, most dogs can live without major restrictions.
Prävention
The prevention of the mdr1 gene defect begins with genetic testing of breeding animals. By identifying and eliminating carriers of the defective gene from the breeding pool, the spread of the mutation in future generations can be reduced. This requires careful breeding practices as well as collaboration between breeders, veterinarians, and geneticists.
For dogs already affected by the mutation, the best prevention is avoiding medications that can trigger adverse reactions. Pet owners should be well informed and ensure that all of the dog’s medical caregivers are aware of its mdr1 status. Regular veterinary checkups and collaboration with an experienced veterinarian can help minimize the risk of adverse drug reactions.
For more information and research findings on this topic, visit the [American Veterinary Medical Association](https://www.avma.org) and the [Washington State University Veterinary Clinical Pharmacology Laboratory](https://vcpl.vetmed.wsu.edu).
Ausblick auf aktuelle Forschung
The MDR1 gene defect, also known as ivermectin sensitivity, is a genetic condition in dogs that has received increased attention in scientific research in recent years. This defect affects the Multidrug Resistance Gene (MDR1), which is responsible for the production of a protein known as P-glycoprotein. This protein plays a crucial role in protecting the brain from potentially toxic substances by actively pumping them out of cells. Dogs with an MDR1 gene defect do not produce this protein sufficiently, making them more sensitive to certain medications, including ivermectin, a commonly used deworming agent.
Research is currently focused on identifying the prevalence of the MDR1 defect in different dog breeds. Studies have shown that the defect occurs particularly frequently in Collies, Australian Shepherds, Shetland Sheepdogs, and other herding dog breeds. Genetic tests are now widely available and enable veterinarians and owners to determine the presence of a defect in a dog before certain medications are administered. This helps minimize the risk of serious side effects.
Another focus of current research is the development of safe treatment strategies for dogs with the MDR1 gene defect. Scientists are investigating alternative medications and dosage adjustments to ensure that affected dogs can be treated effectively and safely. In addition, studies are being conducted to better understand the molecular mechanisms underlying drug sensitivity. These insights could lead in the long term to the development of new therapeutic approaches specifically tailored to dogs with the MDR1 defect.
Research into the genetics of the MDR1 defect is also ongoing. Scientists are working to map the genetic variations and mutations that lead to this defect. This knowledge could contribute to breeding dogs that are free of the defect, supporting the long-term goal of the breeding community to reduce the prevalence of the MDR1 defect. Genetic research has already made significant progress, but further studies are needed to fully understand the complexity of this problem.
In addition to genetic and pharmacological investigations, scientists are studying the effects of the MDR1 defect on the behavior and quality of life of affected dogs. Some studies suggest that the defect may not only affect drug sensitivity but could also cause subtle changes in behavior or neurological function. This research is still in its early stages, but it could provide valuable information about how significantly the MDR1 defect actually affects the life of an affected dog.
Frequently Asked Questions (FAQs)
1. What is the MDR1 gene defect in dogs?
2. Which breeds are most commonly affected by the MDR1 defect?
3. How can it be determined whether a dog has the MDR1 defect?
4. Which medications are dangerous for dogs with the MDR1 defect?
5. What symptoms occur with drug hypersensitivity?
6. Can the MDR1 gene defect be cured?
7. Are there alternative treatments for dogs with the MDR1 defect?
8. How can I prevent my dog from passing on the MDR1 defect?
9. Does the MDR1 defect affect my dog's behavior?
10. How can I reduce the MDR1 defect in the dog population?
Literatur
- Mealey, K. L., Bentjen, S. A., Gay, J. M., & Cantor, G. H. (2001). Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics, 11(8), 727–733. https://doi.org/10.1097/00008571-200111000-00012
- Roulet, A., Puel, O., Gesta, S., Lepage, J.-F., Drag, M., Soll, M., Alvinerie, M., & Pineau, T. (2003). MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. European Journal of Pharmacology, 460(2–3), 85–91. https://doi.org/10.1016/S0014-2999(02)02955-2
- Mealey, K. L. (2004). Therapeutic implications of the MDR-1 gene. Journal of Veterinary Pharmacology and Therapeutics, 27(5), 257–264. https://doi.org/10.1111/j.1365-2885.2004.00607.x
- Gramer, I., Leidolf, R., Döring, B., Klintzsch, S., Krämer, E.-M., Yalcin, E., Petzinger, E., & Geyer, J. (2011). Breed distribution of the nt230(del4) MDR1 mutation in dogs. The Veterinary Journal, 189(1), 67–71. https://doi.org/10.1016/j.tvjl.2010.06.012
- Geyer, J., & Janko, C. (2012). Treatment of MDR1 mutant dogs with macrocyclic lactones. Current Pharmaceutical Biotechnology, 13(6), 969–986. https://doi.org/10.2174/138920112800399301
- Beckers, E., Casselman, I., Soudant, E., Daminet, S., Paepe, D., Peelman, L., & Broeckx, B. J. G. (2022). The prevalence of the ABCB1-1Δ variant in a clinical veterinary setting: The risk of not genotyping. PLOS ONE, 17(8), Article e0273706. https://doi.org/10.1371/journal.pone.0273706
- Mealey, K. L., Owens, J. G., & Freeman, E. (2023). Canine and feline P-glycoprotein deficiency: What we know and where we need to go. Journal of Veterinary Pharmacology and Therapeutics, 46(1), 1–16. https://doi.org/10.1111/jvp.13102
- Mealey, K. L., Fidel, J., Gay, J. M., Impellizeri, J. A., Clifford, C. A., & Bergman, P. J. (2008). ABCB1-1Δ polymorphism can predict hematologic toxicity in dogs treated with vincristine. Journal of Veterinary Internal Medicine, 22(4), 996–1000. https://doi.org/10.1111/j.1939-1676.2008.0122.x